An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Among Patients Aged 18 Years and Older Diagnosed With Non-Cancer Pain and Treated With Opioids Chronically
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Naloxegol (Primary)
- Indications Constipation
- Focus Adverse reactions
- Sponsors AstraZeneca
- 03 Aug 2016 Status changed from not yet recruiting to recruiting.
- 11 Jul 2016 Planned initiation date changed from 1 Jun 2016 to 1 Jul 2016.
- 11 Jul 2016 New trial record